INOVIO Announces Positive Data from Phase 2 Segment of Clinica...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire-AsiaNet/ -- -- INO-4800 was shown to be safe, well-tolerated and immunogenic in allage groups-- Phase 2 results informed INOVIO's selection of 2.0 mg dose for thePhase 3 segment of the trial-- Data published as a preprint in MedR...
Authors: LATEST ASIANET NEWS RELEASES
